Idiopathic Intracranial Hypertension (IIH)

🧠 Standard of Care & Symptoms

Idiopathic Intracranial Hypertension (IIH), historically known as pseudotumor cerebri, is a clinical syndrome characterized by increased intracranial pressure (ICP) of unknown etiology, primarily affecting young, overweight females. Left untreated, chronic pressure on the optic nerves risks permanent vision loss.

• Presentation: Key symptoms.
  • *Pulsatile Headaches:* Severe, daily headaches, frequently described as throbbing or pulsatile, often worsening upon waking or bending forward.
  • *Transient Visual Obscurations:* Brief, temporary episodes of dimmed or blacked-out vision, typically lasting seconds and triggered by changes in posture (e.g. standing up).
  • *Pulsatile Tinnitus:* A rhythmic "whooshing" or beating sound in one or both ears that synchronizes with the patient's heartbeat.
  • *Visual Impairments:* Progressive constriction of peripheral visual fields and double vision (diplopia) due to pressure-induced abducens nerve (CN VI) palsy.

🧬 Diagnostics & Intracranial Pathophysiology

Diagnosis requires brain neuroimaging to exclude structural masses, a lumbar puncture to measure opening pressure, and a comprehensive ophthalmologic exam.

• Diagnostic Markers: Key criteria.
  • Brain MRI/MRV: Excludes space-occupying lesions or venous sinus thrombosis. Key signs of elevated ICP include an **empty sella turcica**, flattening of the posterior sclera, distension of the optic nerve sheaths, and bilateral **transverse venous sinus stenosis**.
  • Lumbar Puncture (LP): Performed in the lateral decubitus position. Confirms elevated CSF **opening pressure** (>250 mm H2O in adults; >280 mm H2O in children) with normal CSF cell counts and chemical composition.
  • Fundoscopic Examination: Demonstrates bilateral **papilledema** (optic disc swelling). Automated visual field testing (Humphrey Perimetry) is required to map and track blind spot enlargement and peripheral vision deficits.

Pathophysiology of Intracranial Hypertension

The development of elevated pressure in IIH involves several physiological factors:

• CSF Absorption Disruption: Elevated pressure is primarily driven by resistance to cerebrospinal fluid (CSF) absorption at the level of the **arachnoid villi** or elevated cerebral venous pressure.
• Venous Sinus Stenosis: Stenosis of the transverse venous sinuses increases intracranial venous pressure. This creates a feedback loop: high tissue pressure collapses the sinus, further restricting venous flow and CSF drainage.
• Optic Nerve Compression: High CSF pressure is transmitted down the subarachnoid space surrounding the optic nerve. This mechanical force blocks axoplasmic transport in the optic nerve fibers, leading to axonal swelling (papilledema), localized ischemia, and progressive optic nerve atrophy.

💊 Medical Reduction & Surgical Decompression

Therapy focuses on lowering intracranial pressure to alleviate headaches and preserve optic nerve function.

Medical Interventions

• Carbonic Anhydrase Inhibitors (Acetazolamide): First-line pharmacotherapy. **Acetazolamide** (1-4 g daily in divided doses) reduces CSF secretion by choroid plexus cells. Side effects include finger/toe paresthesias, metabolic acidosis, and fatigue.
• Topiramate: Often used as an alternative or adjunct. It possesses weak carbonic anhydrase inhibitor activity, helps prevent headaches, and facilitates weight loss.
• Weight Loss: A structured, moderate-to-severe weight loss program (reduction of 5% to 10% of body weight) is highly effective at reducing venous pressure, lowering ICP, and inducing long-term disease remission.

Surgical & Interventional Procedures

• Optic Nerve Sheath Fenestration (ONSF): Deployed for patients with progressive, threat-to-vision papilledema despite maximal medical therapy. Slits are cut into the optic nerve sheath to allow CSF to drain into the orbit, reducing pressure on the nerve fibers.
• Transverse Venous Sinus Stenting: In patients with severe transverse venous sinus stenosis and a documented pressure gradient, a stent is endovascularly deployed to restore sinus caliber, reduce venous pressure, and normalize CSF drainage.
• CSF Shunting: Ventriculoperitoneal (VP) or lumboperitoneal (LP) shunts are used as a rescue therapy for refractory headaches or progressive vision loss.

🔬 Active Clinical Trials

Clinical trials are currently evaluating GLP-1 receptor agonists to reduce CSF secretion, stenting vs. fenestration efficacy, and new headache prevention protocols.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Idiopathic Intracranial Hypertension, establish these clinical care pathways:

1. Establish Regular Eye Exams: Schedule visual field testing and optical coherence tomography (OCT) of the optic nerve head every 2-4 weeks initially.
2. Begin Acetazolamide Therapy: Work with your neurologist to slowly titrate your dose to minimize side effects like paresthesias (tingling).
3. Design a Weight Loss Program: Partner with a dietitian or weight-management clinic to target a healthy, progressive 5-10% weight loss.
4. Monitor for Vision Changes: Seek immediate medical attention if you experience a sudden decrease in vision or worsening blind spots.

❓ Patient FAQ

Q: Why is IIH sometimes called "pseudotumor cerebri"?
A: "Pseudotumor cerebri" translates to "false brain tumor." This name was used because patients present with symptoms of a brain tumor—severe headaches, pressure, and swelling of the optic nerves (papilledema)—but neuroimaging shows no physical tumor mass.

Q: Can weight loss cure IIH?
A: In many patients, yes. Numerous clinical studies have demonstrated that a weight reduction of 5% to 10% can reduce intra-abdominal and thoracic pressures, thereby lowering cerebral venous pressure and driving IIH into complete remission.